2013 - CTS 2013 Congress

This page contains exclusive content for the member of the following sections: TTS, CTS

Oral Communications 2

6.6 - A new generation of implantable constructs: developing implants that make of the endogenous responses and of the host body respectively the effectors and the bioreactor of tissue regeneration

Presenter: Massimiliano, Gaetani, Palermo, Italy
Authors: Massimiliano Gaetani1,2,3,4, Roberta Tasso1,2,3,4, Ranieri Cancedda1,2,3,4, Pier Giulio Conaldi1,2,3,4

A new generation of implantable constructs: developing implants that make of the endogenous responses and of the host body respectively the effectors and the bioreactor of tissue regeneration

Massimiliano Gaetani1,2,3,4, Roberta Tasso1,2,3,4, Ranieri Cancedda1,2,3,4, Pier Giulio Conaldi1,2,3,4

1Ri.MED Foundation, Palermo, Italy; 2Regenerative Medicine and Biomedical Technologies Unit, ISMETT, Palermo, Italy; 3Department of Oncology, Biology, and Genetics, University of Genoa, Genoa, Italy; 4A.O.U. San Martino - IST (National Cancer Research Institute), Genoa, Italy


Tissue engineering (TE) makes combined use of cells and biomaterials, as scaffolds, in order to restore tissue structure and function mostly thorugh the specific commitment of the implanted cells. Similarly to regenerative medicine and to therapies of immune-related disorders, TE holds many expectations from the use of mesenchymal stem cells (MSCs). For their properties of self-renewal, multipotency, immune system modulation and support for tissue repair and angiogenesis, MSCs are a major current focus of many academic, industrial and clinical interests.
Although MSCs can differentiate into various mesenchymal lineages and even trans-differentiate in culture, when successfully implanted in vivo, the new tissue is never of donor origin nor is justified by the incidence of differentiation of grafted MSCs. Within all human organs and tissues from which they are derived, MSCs are perivascular progenitors and regulate tissue homeostasis, repair and regeneration, leading to recruitment of macrophages, endothelial precursors and host pluripotent cells [1].
We recently showed that ectopic implants, in mice, of osteo-conductive scaffolds seeded with bone marrow (BM)-MCSs leaded to endochondral bone formation only when previously enriched in culture for early progenitors. These MSCs triggered regeneration by secreting bioactive molecules and so modulating the host microenvironment rather than directly differentiating into the injured tissue [2]. Furthermore, like the ability to be enrolled in a specific commitment, the secretion of factors by MSC was shown to be dependent on cell progenitor state, and this activity is likely to be the most important for MSCs therapeutic potential. However, although it is known that MSCs orchestrate regeneration acting as “drugstores”, by secreting a mix of factors that trigger endogenous cascades [3], TE is still based on cells potentially differentiating into the injured tissue and on scaffolds engineered for this goal. Contrarily, engineering products based on biomaterials, cells or their derivates that might bring the microenvironment modulations necessary to induce the host specific tissue regeneration in vivo, is poorly unexplored. Using mass spectrometry-based proteomics, we quantitatively identified the factors specifically secreted by early progenitor BM-MSCs. By deciphering the milieu of secreted proteins and by systems biology analysis we also identified the biological responses that MSCs can induce in vivo [2].
This strategy is currently under further development, in order to understand how to rule TE toward a new generation of implantable constructs not necessarily involving the engraftment of the implanted cells or not even using cells, but ideally being applied as pharmaceutical devices that, if implanted locally within a damaged tissue area, will trigger host regenerative processes, and use the endogenous cells as the effectors and the host body as the bioreactor.

[1] Bianco P, Robey PG, Simmons PJ: Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008, 2:313-9.

[2] Tasso R, Gaetani M, Molino E, Cattaneo A, Monticone M, Bachi A, Cancedda R: The role of bFGF on the ability of MSC to activate endogenous regenerative mech anisms in an ectopic bone formation model. Biomaterials 2012, 33: 2086-96.

[3] Caplan AI, Correa D: The MSC: an injury drugstore. Cell Stem Cell 2011, 9:11-5.



Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.



Staff Directory
This email address is being protected from spambots. You need JavaScript enabled to view it.


The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7